CINRYZE™ is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE. Among adult HAE patients, 51% miss at least one day of work (mean 3.3 days), 44% students miss at least one day of school
Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine Data extend the clinically meaningful benefits of dapagliflozin in patients with heart failure regardless of ejection fraction Heart failure is a chronic, progressive disease impacting nearly 64
